Skip to main content

Advertisement

Table 1 Population characteristics

From: The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient

Characteristic
Demographics
  Male (n (%)) 40 (95.2%)
  Age (years) 63 ± 13.2
  Gout duration (years) 7.9 ± 9.6
  Familial gout (n (%)) 7 (16.7%)
  Number of flares per year 4.1 ± 6.6
  Alcohol consumption (g/day) 15 ± 20.7
  Creatinine clearance (ml/min) 80.0 ± 31.1
Cardiovascular risk factors
  Body mass index (kg/m2) 30.2 ± 5.7
  Total cholesterol (mg/dL) 177 ± 63
  HDL cholesterol (mg/dL) 44 ± 13
  LDL cholesterol (mg/dL) 97 ± 43
  Triglycerides (mg/dL) 207 ± 393
  Systolic blood pressure (mmHg) 132.8 ± 13.7
  Diastolic blood pressure (mmHg) 77 ± 9.9
  Smoker (n (%)) 6 (14.3%)
  Metabolic syndrome (n (%)) 28 (66.7%)
Cardiovascular comorbidities
  Coronary heart disease (n (%)) 6 (14.3%)
  Peripheral arterial disease (n (%)) 3 (7.1%)
  Stroke (n (%)) 3 (7.1%)
  Diabetes mellitus (n (%)) 15 (35.7%)
Cardiovascular risk assessment
  ACC/AHA 10-year risk (%) 21 ± 14
  Framingham 10-year general cardiovascular risk (%) 22 ± 14
  Framingham 10-year coronary risk (%) 15 ± 11
Urate burden
  Serum urate (mg/dL) 8.1 ± 2.3
  Subcutaneous (clinical) tophi (n (%)) 12 (28.6%)
  Ultrasound tophus (n (%)) 29 (69%)
  Ultrasound tophus volume (cm3) 1.1 ± 1.4
  At least one joint with the double contour sign (n (%)) 41 (97.6%)
  DECT MSU volume knees (cm3) (n = 39) 1.9 ± 4.6
  DECT MSU volume feet (cm3) (n = 41) 2.7 ± 6.7
  DECT MSU volume knees + feet (cm3) (n = 38) 4.7 ± 10.8
Ongoing drugs
  Diuretics (n (%)) 11 (26.2%)
  Antidiabetic treatment (n (%)) 15 (35.7%)
  Hypolipidemic treatment (n (%)) 16 (38.1%)
  Treatment for high blood pressure (n (%)) 25 (59.5%)
  1. ACC/AHA American College of Cardiology/American Heart Association, DECT dual-energy computed tomography, HDL high-density lipoprotein, LDL low-density lipoprotein, MSU monosodium urate